SCHEMBL3958950

SCHEMBL3958950

NC(=O)c1ccccc1N1CCC[C@H](CNC(=O)C(F)(F)F)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.49
RPS6KB1 P23443 9/20 0.45
AKT1 P31749 1/20 0.45
BTK Q06187 1/20 0.43
CKS1B P61024 1/20 0.42
SKP1 P63208 1/20 0.42
SKP2 Q13309 1/20 0.42
PTPN1 P18031 1/20 0.41
GAA P10253 1/20 0.40
BCHE P06276 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39
PDK3 Q15120 1/20 0.39
PDK4 Q16654 1/20 0.39
MEN1 O00255 1/20 0.38
PLA2G1B P04054 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
ATG4B Q9Y4P1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3953517 1.00 NPC1 (0.49) NPC1RPS6KB1AKT1BTKCKS1B
SCHEMBL3953520 1.00 NPC1 (0.49) NPC1RPS6KB1AKT1BTKCKS1B
SCHEMBL14206763 0.87 CKS1B (0.44) RPS6KB1AKT1BTKCKS1BSKP1
SCHEMBL14206406 0.87 CKS1B (0.44) RPS6KB1AKT1BTKCKS1BSKP1
SCHEMBL14330893 0.83 CKS1B (0.42) BTKCKS1BSKP1SKP2PTPN1
SCHEMBL14330872 0.83 CKS1B (0.42) BTKCKS1BSKP1SKP2PTPN1
SCHEMBL14206405 0.81 LMNA (0.53) CKS1BSKP1SKP2GAAALDH1A1
SCHEMBL14206762 0.81 LMNA (0.53) CKS1BSKP1SKP2GAAALDH1A1
SCHEMBL2556561 0.78 NPC1 (0.57) NPC1RPS6KB1AKT1PTPN1GAA
SCHEMBL11908438 0.73 NPC1 (0.65) NPC1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2078003-B1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME (US) 2017-03-08 EP disclosed
US-9206142-B2 Anilinopiperazine derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2015-12-08 US disclosed
US-20120328691-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC 2012-12-27 US disclosed
EP-2078003-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2009-07-15 EP disclosed
WO-2008054702-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120328691-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MAPK15, CDK15, MAPKAPK5 NPC1 2310/4885RPS6KB1 1790/4885AKT1 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.